| Basics |
Corvus Pharmaceuticals, Inc. Common Stock
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It is engaged in development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells.
|
| IPO Date: |
March 21, 2016 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$459.01M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.19 | 3.69%
|
| Avg Daily Range (30 D): |
$0.13 | 2.65%
|
| Avg Daily Range (90 D): |
$0.13 | 3.04%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.52M |
| Avg Daily Volume (30 D): |
.49M |
| Avg Daily Volume (90 D): |
.75M |
| Trade Size |
| Avg Trade Size (Sh.): |
197 |
| Avg Trade Size (Sh.) (30 D): |
97 |
| Avg Trade Size (Sh.) (90 D): |
118 |
| Institutional Trades |
| Total Inst.Trades: |
124 |
| Avg Inst. Trade: |
$1.57M |
| Avg Inst. Trade (30 D): |
$5.8M |
| Avg Inst. Trade (90 D): |
$3.96M |
| Avg Inst. Trade Volume: |
.27M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.39M |
| Avg Closing Trade (30 D): |
$18.62M |
| Avg Closing Trade (90 D): |
$10.52M |
| Avg Closing Volume: |
435.61K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-.66
|
$-.1
|
$.21
|
|
Diluted EPS
|
$-1.02
|
$-.1
|
$-.13
|
|
Revenue
|
$ M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -45.14M
|
$ -8M
|
$ 15.19M
|
|
Operating Income / Loss
|
$ -35.54M
|
$ -10.26M
|
$ -9.92M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -.15M
|
$ 9.69M
|
$ -3.74M
|
|
PE Ratio
|
|
|
|
|
|
|
